Kazia Therapeutics Shows Promise with Tumor Reduction in TNBC
Kazia Therapeutics Limited (NASDAQ: KZIA) has announced a remarkable breakthrough in oncology with an 86% reduction in tumor burden observed in a patient with metastatic triple-negative breast cancer (TNBC). This achievement comes from an expanded access case where the patient received a combination treatment involving the company's investigational drug, paxalisib, along with immunotherapy and chemotherapy. This innovative approach marks a significant advancement in the treatment of a challenging cancer type.
Patient's Journey to Recovery
The patient, a woman in her 40s, was first diagnosed with TNBC a couple of years back. Following a protocol that included neoadjuvant chemotherapy and bilateral mastectomy, she initially showed promising results with no residual tumor remaining. However, the malignancy returned aggressively, resulting in metastatic disease affecting her bones and lungs. As a result, she was enrolled in a single-patient expanded-access protocol, where she received an integrative therapy regimens combining paxalisib with immunotherapy and chemotherapy.
Impressive Clinical Results Supported by Science
After just three weeks of this dual therapy, imaging scans indicated an astounding 86% reduction in overall tumor volume. Dr. John Friend, Chief Executive Officer of Kazia Therapeutics, expressed optimism regarding the rapid and profound tumor regression, noting that it aligns with the biological principles underpinning the use of paxalisib in combination with immune checkpoint inhibitors. This case not only reflects the potential effectiveness of their treatment strategy but also reinforces the company’s commitment to advancing its ongoing clinical trials.
The Phase 1b TNBC Trial: Exploring New Horizons
Kazia is currently conducting extensive multi-center Phase 1b trials to explore the effectiveness of paxalisib in conjunction with Keytruda® (pembrolizumab) and chemotherapy specifically for advanced breast cancer cases, including TNBC. The focus of this study is to assess safety, determine preliminary anti-tumor activity, and identify relevant biomarkers that can provide insights into how paxalisib modifies tumor dynamics and aids in enhancing responses to immunotherapy.
Expanding Horizons in Cancer Treatment
Kazia Therapeutics is dedicated to the continuous development of paxalisib, which is an investigational inhibitor targeting the PI3K/Akt/mTOR pathway, utilized for various cancer types. Since its inception, the drug has undergone rigorous studies, including a completed Phase 2/3 clinical trial in glioblastoma. Currently, ongoing research includes several indications, such as advanced breast cancer and primary central nervous system lymphoma, among others. The potential for paxalisib to significantly alter treatment landscapes is supported by its designation as an Orphan Drug by the FDA.
For Media Inquiries
For further information, inquiries from media and investors should be directed to Alex Star, Managing Director at LifeSci Advisors LLC, via email at Astarr@lifesciadvisors.com or by phone at +1-201-786-8795.
About Kazia Therapeutics
Kazia Therapeutics Limited (NASDAQ: KZIA), based in Sydney, Australia, is focused on developing groundbreaking therapeutic strategies in oncology. The company's lead investigational agent, paxalisib, is being assessed for multiple cancers, aiming to improve outcomes through targeted inhibition of specific signaling pathways. Their commitment to innovation extends beyond their ongoing trials, as Kazia seeks to contribute significantly to the evolving landscape of cancer therapies.
Frequently Asked Questions
What was the main finding of Kazia's recent announcement?
Kazia Therapeutics reported an 86% reduction in tumor burden in a TNBC patient treated with paxalisib combined with immunotherapy and chemotherapy.
Who is the CEO of Kazia Therapeutics?
The CEO of Kazia Therapeutics is Dr. John Friend, who highlighted the encouraging results observed in the patient.
What is the focus of the ongoing Phase 1b trial?
The Phase 1b trial is evaluating paxalisib's safety and efficacy in combination with Keytruda and chemotherapy for patients with advanced breast cancer.
Where is Kazia Therapeutics based?
Kazia Therapeutics is based in Sydney, Australia, and is dedicated to innovative oncology drug development.
How can investors contact Kazia Therapeutics?
Investors can reach out to Alex Star at LifeSci Advisors LLC via email at Astarr@lifesciadvisors.com or by phone at +1-201-786-8795.
